Patents by Inventor Uttam SURANA

Uttam SURANA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOUNDS FOR TREATMENT OF CANCER
    Publication number: 20220315587
    Abstract: Compounds of formula I as defined herein, or pharmaceutically acceptable salts, solvates or derivatives thereof, are potent inhibitors of angiogenesis and accordingly are of use in the treatment and prevention of various angiogenesis-related disorders such as macular degeneration and diabetic retinopathy.
    Type: Application
    Filed: June 25, 2020
    Publication date: October 6, 2022
    Inventors: Srinivasaraghavan KANNAN, Hong Hwa LIM, Chandra Shekhar VERMA, Uttam SURANA
  • COMPOUNDS FOR TREATMENT OF EYE DISORDERS
    Publication number: 20220242863
    Abstract: Compounds of formula I as defined herein, or pharmaceutically acceptable salts, solvates or derivatives thereof, are potent inhibitors of angiogenesis and accordingly are of use in the treatment and prevention of various angiogenesis-related disorders such as cancer.
    Type: Application
    Filed: June 25, 2020
    Publication date: August 4, 2022
    Inventors: Srinivasaraghavan KANNAN, Hong Hwa LIM, Chandra Shekhar VERMA, Uttam SURANA
  • Antisense oligonucleotides
    Patent number: 11072795
    Abstract: The present invention relates to antisense oligonucleotides for modulating the activity of glycine decarboxylase (GLDC). In particular, the present invention relates to antisense oligonucleotides capable of inducing exon skipping of RNA. Also claimed are pharmaceutical compositions, kits and methods of treating cancer and inducing exon-skipping using said antisense oligonucleotides. In addition, a method for aiding the categorising or determining prognosis of a cancer or in selecting a therapeutic strategy for a patient with cancer, based on assessing the level of GLDC nucleic acid, protein or activity in a sample derived from the patient is provided.
    Type: Grant
    Filed: October 16, 2017
    Date of Patent: July 27, 2021
    Assignee: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
    Inventors: Uttam Surana, Dave Keng Boon Wee, Jing Lin, Bing Lim
  • ANTISENSE OLIGONUCLEOTIDES
    Publication number: 20190309302
    Abstract: The present invention relates to antisense oligonucleotides for modulating the activity of glycine decarboxylase (GLDC). In particular, the present invention relates to antisense oligonucleotides capable of inducing exon skipping of RNA. Also claimed are pharmaceutical compositions, kits and methods of treating cancer and inducing exon-skipping using said antisense oligonucleotides. In addition, a method for aiding the categorising or determining prognosis of a cancer or in selecting a therapeutic strategy for a patient with cancer, based on assessing the level of GLDC nucleic acid, protein or activity in a sample derived from the patient is provided.
    Type: Application
    Filed: October 16, 2017
    Publication date: October 10, 2019
    Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH
    Inventors: Uttam SURANA, Keng Boon WEE, Jing LIN, Bing LIM